Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

BACKGROUND AND OBJECTIVES: Short-term studies focused on once-monthly paliperidone palmitate (PP) at doses of 25 mg eq, 50 mg eq, 75 mg eq, 100 mg eq, or 150 mg eq have shown its efficacy and tolerability in the treatment of schizophrenia patients. However, few open-label and long-term studies are a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Patient Prefer Adherence
Egile Nagusiak: González-Rodríguez, Alexandre, Catalán, Rosa, Penadés, Rafael, Garcia-Rizo, Clemente, Bioque, Miquel, Parellada, Eduard, Bernardo, Miquel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2015
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459629/
https://ncbi.nlm.nih.gov/pubmed/26082620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S63948
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak